Matthew Quinn Reber

Partner at 1315 Capital LLC

Matthew Quinn Reber

Matthew Quinn Reber

Partner at 1315 Capital LLC

Overview
RelSci Relationships

259

Number of Boards

2

Contact Data
Trying to get in touch with Matthew Quinn Reber? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Matthew Quinn Reber likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Healthcare Royalty Management LLC

Relationship likelihood: Strong

Managing Director at Cowen Healthcare Royalty Management LLC

Relationship likelihood: Strong

Founder at Nuron Biotech, Inc.

Relationship likelihood: Strong

Advisor & Operating Partner at Healthcare Royalty Management LLC

Relationship likelihood: Strong

Co-Founder at Onkos Surgical, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Innovative Health LLC

Relationship likelihood: Strong

Co-Founder at Onkos Surgical, Inc.

Relationship likelihood: Strong

Partner & Chief Medical Officer at Healthcare Royalty Management LLC

Relationship likelihood: Strong

Founder at Healthcare Royalty Management LLC

Relationship likelihood: Strong

Vice President & Controller at Abbott Nutrition Manufacturing, Inc.

Relationship likelihood: Strong

Paths to Matthew Quinn Reber
Potential Connections via
Relationship Science
You
Matthew Quinn Reber
Partner at 1315 Capital LLC
Education
Class of 2005

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

Class of 1998

Princeton University is a vibrant community of scholarship and learning that stands in the nation's service and in the service of all nations. Chartered in 1746, Princeton is the fourth-oldest college in the United States. Princeton is an independent, coeducational, nondenominational institution that provides undergraduate and graduate instruction in the humanities, social sciences, natural sciences and engineering. As a world-renowned research university, Princeton seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding. At the same time, Princeton is distinctive among research universities in its commitment to undergraduate teaching. Today, more than 1,100 faculty members instruct approximately 5,000 undergraduate students and 2,500 graduate students. The University's generous financial aid program ensures that talented students from all economic backgrounds can afford a Princeton education.

MBA

The Wharton School is the business school of the University of Pennsylvania, an Ivy League university in Philadelphia, Pennsylvania. Wharton was the world’s first collegiate business school and the first business school in the United States. It was established in 1881 through a donation of Joseph Wharton.

Career History
Managing Director
2008 - Prior

Healthcare Royalty Management invests primarily in commercial stage healthcare companies, pharmaceutical, biotechnology and products through the purchase of traditional passive royalties, the creation of synthetic royalties, structured debt and equity instruments. The firm focus on healthcare companies and products across a broad range of therapeutic areas predominately in the US and European Union. They targets investments of $20 million to $200 million. They provides financing capital to assist in the transfer of product and execution risk, finance new development opportunities, acquire new products or technologies, fund additional capital needs and monetize product royalties.

Associate
2005 - 2006

Paul Capital Partners' investment platforms include the Paul Capital Fund of Funds, secondary investments and commercial-stage healthcare investments.The Paul Capital Fund of Funds investment team focuses on investments in venture capital and small-cap buyouts. The firm invests in funds that support innovative products and business models. They take takes a lead investment role and actively seek advisory board seats. Their strategy is both growth and value oriented.The Paul Capital Fund of Funds venture capital investment strategy focuses on providing access to top-tier venture capital managers. The firm looks for emerging managers that have the potential to become industry leaders. They employ a multi-industry investment strategy that focuses on information technology, healthcare and clean technology. Most investments are made in early-stage companies, but some investments are made in late-stage and growth equity to provide reduced volatility and more rapid exits. The strategy is biased towards small funds and is balanced by a short list of larger funds or platforms. Paul Capital invests primarily in funds in the Silicon Valley and Boston, with growing exposure to select international investments. They make secondary investments in top tier managers obtained through the secondary market to mitigate the effect of the typical J-Curve associated with private equity fund investing.The Paul Capital Fund of Funds small-cap buyout investment strategy focuses on investments in a small-cap buyout funds in North America. They invest in small-cap buyout funds that are being raised by managers who are focused on buying companies with enterprise values of $300 million or less. To select the best performing managers, Paul Capital's process begins with a large universe of buyout relationships and ends with a focused and diversified small-cap buyout portfolio. The portfolio is complemented by co-investments and by investments in target funds obtained through the secondary market.The Paul Capital Fund of Funds co-investment strategy focuses on co-investments alongside general partners that are well-known to the firm and who require capital to close pending small-cap buyout and growth equity transactions. Investments are made directly in the securities of the portfolio company. The Fund of Funds team invests directly in portfolio companies across a full range of economic and credit cycles.For investors requiring exposure to both the firm's venture capital and small-cap buyout funds, Paul Capital provides customized solutions that allow participation in both activities over a multi-year period with a desired percentage allocation to each. Large investors seeking increased exposure to emerging managers, growth equity funds or buyout funds larger than their small-cap target (but generally less than $2 billion in size) can be accommodated through a separate account relationship.Paul Capital provides secondary transaction solutions for various sellers including pension plans, financial institutions, endowments, family offices, corporations and general partners.They help sellers reallocate their portfolio across asset types and classes, achieve early liquidity from private equity investments and obtain follow-on capital for existing portfolios and other objectives.Paul Capital Healthcare employs a variety of financing options ranging from non-dilutive financings that include royalty and revenue interest financings, to more traditional instruments such as equity and structured debt. Their clients include public and private companies, academic institutions and inventors. Paul Capital Healthcare helps companies monetize their royalty streams by selling all or a portion of these future royalties in exchange for an upfront payment and, depending on the structure, potential future payments. Paul Capital Healthcare invests in healthcare products that are approved and are generating revenue or are near commercialization. Healthcare companies should have an identifiable and established market, have patent and/or regulatory protection and be marketed by a strong organization.Paul Capital Healthcare employs the use of synthetic royalties or revenue interest financings. The firm provides a company with an upfront payment and future payments in exchange for a percentage of future product revenues. These deals are structured in a way that is similar to licensing agreements. They employ tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options. The deals are different from a standard licensing agreement in that Paul Capital Healthcare is not responsible for commercializing the product and is not involved in the company's daily operations. The firm makes an upfront payment to the company and, in some cases, additional payments based on certain milestones, such as regulatory approvals, patent extensions and sales targets. Paul Capital Healthcare then receives a portion of the future revenues generated by the product(s).Paul Capital Healthcare provides structured debt financing for small to mid-sized healthcare companies looking to expand operations. They can structure mezzanine-like debt in combination with revenue interests or royalty financings and the purchase of equities.Paul Capital Healthcare also structures traditional equity investments, usually in combination with revenue interest and royalty financings. The Fund participates in early-stage financing rounds in syndication with venture funds and in PIPE-style offerings. Paul Capital Healthcare focuses on near market or commercial-stage investments.

Vice President
2008 - 2009

Cowen Group, Inc. provides investment banking for small to midsized companies in the alternative energy, consumer health care, media, technology, and telecommunications industries. It offers mergers and acquisitions advice, securities underwriting, equity offerings, private equity placements, and market-making. The company was founded in 1918 and is headquartered in New York, NY.

Boards & Committees
Director
Current

Helomics Corp. provides cancer care development and treatment consulting services. Its products include chemoFx, biospeciFx, geneFx colon and geneFx lung. It also offers research and development services. The company was founded in 1995 and is headquartered in Pittsburgh, PA.

Director
Current

Nuron Biotech, Inc. markets and develops vaccines for the prevention and treatment of infectious diseases. It develops novel biologics and vaccines for the prevention and treatment of neurodegenerative and infectious diseases. The firm is advancing products to meet unmet medical needs in the areas of multiple sclerosis, alzheimer's, hepatitis b and hepatitis c for patients across the globe. The company was founded by Vithalbhai Dhaduk, Shankar Musunuri and David Zeng in 2009 and is headquartered in Exton, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Matthew Quinn Reber. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Matthew Quinn Reber's profile does not indicate a business or promotional relationship of any kind between RelSci and Matthew Quinn Reber.